You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 20, 2024

Investigational Drug Information for Irsogladine

✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Irsogladine?

Irsogladine is an investigational drug.

There have been 4 clinical trials for Irsogladine. The most recent clinical trial was a Phase 1 trial, which was initiated on February 1st 2022.

The most common disease conditions in clinical trials are Peptic Ulcer, Wounds and Injuries, and Gastritis. The leading clinical trial sponsors are Boryung Pharmaceutical Co., Ltd, The Catholic University of Korea, and Kukje Pharma.

There are zero US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Irsogladine
Therapeutic Effect of Isoladine Maleate on Small Intestinal Mucosal Injury Associated With NSAIDS in PopulationLee's Pharmaceutical LimitedPhase 4
[KJ-INT-002] BE StudyKukje PharmaPhase 1
A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate TabletBoryung Pharmaceutical Co., LtdPhase 1

See all Irsogladine clinical trials

Clinical Trial Summary for Irsogladine

Top disease conditions for Irsogladine
Top clinical trial sponsors for Irsogladine

See all Irsogladine clinical trials

US Patents for Irsogladine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Irsogladine ⤷  Sign Up Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) ⤷  Sign Up
Irsogladine ⤷  Sign Up Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) ⤷  Sign Up
Irsogladine ⤷  Sign Up Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) ⤷  Sign Up
Irsogladine ⤷  Sign Up Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) ⤷  Sign Up
Irsogladine ⤷  Sign Up Inhibition of hypoxia-inducible factor activity with carica papaya extracts The Regents of the University of California (Oakland, CA) Universiti Putra Malaysia (Selangor Darul Ehsan, MY) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Irsogladine

Drugname Country Document Number Estimated Expiration Related US Patent
Irsogladine Australia AU2006213610 2025-02-10 ⤷  Sign Up
Irsogladine Canada CA2596845 2025-02-10 ⤷  Sign Up
Irsogladine Denmark DK1851340 2025-02-10 ⤷  Sign Up
Irsogladine European Patent Office EP1851340 2025-02-10 ⤷  Sign Up
Irsogladine Hong Kong HK1115165 2025-02-10 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.